Benjamin Neel

Benjamin Neel at NYU has made foundational contributions to SHP2 phosphatase biology and the development of SHP2 inhibitors as cancer therapeutics. His research established that SHP2 is a critical node in RTK-RAS signaling and identified SHP2 as a key mediator of adaptive feedback resistance to KRAS inhibitors. He contributed to the scientific rationale for SHP2 inhibitor development and their evaluation in combination with KRAS G12C inhibitors. His work on SHP2 in hematopoietic malignancies and solid tumors has identified relevant contexts where SHP2 inhibition provides therapeutic benefit.